InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,615.35
(
0.55%
)
US TECH 100
19,804.00
(
0.64%
)
Dow Jones
40,000.90
(
0.62%
)
Brent Oil
84.57
(
0.00%
)
Bitcoin
60,109.59
(
1.48%
)
Post# of 252591
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dangerM post# 224644

Saturday, 04/13/2019 5:13:39 PM

Saturday, April 13, 2019 5:13:39 PM

Post# of 252591
SBPH addendum: Listened to the webcast and studies the CC slides. I don't see any particular reason to be optimistic about the outcomes of the phase-2b trials (just getting underway) other than in showing Inarigivir could have a place as salvage therapy for patients with nuke resistance. But this is not the big market that other HBV players are pursuing.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up